Endocrine surgeons primarily focus on the thyroid, parathyroid, and adrenal glands. For the thyroid, their work often ...

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

The US Food and Drug Administration has approved crinecerfont for treating congenital CAH in combination with glucocorticoids ...

Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel ...

SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control ...

The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

"Today's approval provides an important advance for patients with classic congenital adrenal hyperplasia and highlights the FDA's continued commitment to advancing effective and safe treatments ...

"Today's approval provides an important advance for patients with classic congenital adrenal hyperplasia and highlights the FDA's continued commitment to advancing effective and safe treatments for ...